Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Read more about Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Determination of melphalan in human plasma by UPLC-UV method. Read more about Determination of melphalan in human plasma by UPLC-UV method.
A note on improved statistical approaches to account for pseudoprogression. Read more about A note on improved statistical approaches to account for pseudoprogression.
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Read more about Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Read more about A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation. Read more about Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Read more about Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
Direct and indirect targeting of MYC to treat acute myeloid leukemia. Read more about Direct and indirect targeting of MYC to treat acute myeloid leukemia.
Anticancer activity of VDR-coregulator inhibitor PS121912. Read more about Anticancer activity of VDR-coregulator inhibitor PS121912.
Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Read more about Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.
